Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors.
Messer WS Jr, Rajeswaran WG, Cao Y, Zhang HJ, el-Assadi AA, Dockery C, Liske J, O'Brien J, Williams FE, Huang XP, Wroblewski ME, Nagy PI, Peseckis SM.
Messer WS Jr, et al.
Pharm Acta Helv. 2000 Mar;74(2-3):135-40. doi: 10.1016/s0031-6865(99)00026-6.
Pharm Acta Helv. 2000.
PMID: 10812950
Cholinergic neurons degenerate in Alzheimer's disease, resulting in cognitive impairments and memory deficits, and drug development efforts have focused on selective M1 muscarinic agonists. 5-(3-Ethyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine trifluoroacetic acid (CDD-0 …
Cholinergic neurons degenerate in Alzheimer's disease, resulting in cognitive impairments and memory deficits, and drug development efforts …